Congruence Therapeutics
PrivateLast Round
VC Round
Mar 19, 2026
Total Funding Raised
$98M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Congruence Therapeutics is a biotechnology company that develops small molecule correctors to rescue aberrant protein function in protein misfolding diseases using a proprietary computational drug discovery platform.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Medical AI, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Congruence Therapeutics Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
Congruence Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Mar 19, 2026 | ||||
| Early Funding | Sep 4, 2025 | ||||
| Grant | Jul 24, 2025 | ||||
| Series A Extension | Mar 6, 2023 | ||||
| Series A | Feb 8, 2022 |
Key People
Founding team and executive leadership
Congruence Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Investissement Québec | Early Funding, Series A, VC Round, Series A Extension |
| Amplitude Ventures | Early Funding, VC Round, Series A Extension, Series A |
| Fonds de solidarité FTQ | Early Funding, VC Round, Series A Extension, Series A |
| BDC Capital | Early Funding, VC Round |
| OrbiMed | Early Funding, Series A, VC Round, Series A Extension |
| The Michael J. Fox Foundation for Parkinson's Research | Grant |
| Alexandria Venture Investments | Early Funding |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 9, 2026
Attending the 25th Annual Needham Virtual Healthcare Conference.
- Apr 8, 2026
Launched Revenir™ for identifying novel binding sites.
Congruence Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Congruence Therapeutics's valuation, stock price, and market status.